Brexit: Advising Companies To Prepare For Only The Worst Case Scenario Is Premature, Says BIA
Executive Summary
The European Medicines Agency has issued figures on the number of UK-based sponsors of orphan medicines, and qualified persons for pharmacovigilance – both of which will be affected when the UK leaves the EU. However, UK BioIndustry Association thinks advising companies on changes they will have to make may be premature as it is yet to be decided what role, if any, the UK will have in the EU medicines network following Brexit.
You may also be interested in...
EMA To Contact Sponsors Of Over 100 Drugs At Risk Of Shortage Post Brexit
The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.
Brexit: How Do Pharma Firms Plan For An Unknown Scenario?
As the Brexit negotiations continue, the pharmaceutical industry is anxious to have a cut-off date when it should start taking action to deal with the legal repercussions of the UK becoming a third country within the context of the EU medicines network. There are no clear answers yet, and companies are being asked to continue to wait and watch.
Change And More Change: That’s What Brexit Means For Drug Companies
The EU medicines network has issued a long list of changes that drug companies with activities in the UK will have to make if they are to continue to be located from a regulatory standpoint in the European Economic Area following Brexit. Aspects affected include the location of orphan designation holders, qualified persons for pharmacovigilance, companies’ manufacturing and batch release sites and maintenance of SME status.